HTLV-1 orf-I is important for immune evasion, viral replication and persistence. Here, we analyzed proviral sequences isolated from ex vivo PBMC samples of 163 HTLV-1-infected patients (85 carriers, 78 HAM/TSP). Of the 5000 sequences analyzed, orf-I expression was consistently maintained. While the highest percentage of isolates express both p12 and p8 (69%), the mutants that express mainly p8 (7%) or mainly p12 (24%) were highly correlated with decreased proviral loads. To determine the individual role of p12 and p8 in viral persistence, we constructed infectious molecular clones expressing either p12(G29S) or p8(N26) and established producer cell lines used to infect macaques. Three of four macaques infected with WT-HTLV-1 tested positive by PCR and were seropositive. Only one of the macaques infected with N26-HTLV-1 tested positive by PCR and two macaques were seropositive. None of the 8 animals infected with G29S-HTLV-1 tested PCR positive or seroconverted. These results suggest that expression of both p12 and p8 are critical for viral persistence. Since orf-I plays a role in T-cell activation and recognition, we compared the CTL responses elicited by CD4+ T-cell infected with the different HTLV-1 clones. Although the supernatant p19 levels and proviral loads for all four infected lines were similar, a significant difference in Tax-specific CTL killing was observed. Cells infected with orf-I-knockout virus, p12-G29S or p8-N26 were killed whereas cells infected with WT virus were not killed by Tax-specific CTLs. These results indicate that efficient viral persistence and spread requires expression of both p12 and p8.
. 2014 Jan 7;11(Suppl 1):O13. doi: 10.1186/1742-4690-11-S1-O13
Both orf-I isoforms, p12 and p8, are required for efficient HTLV-1 infection and persistence
Cynthia Pise-Masison
1,✉, Maria Fernanda de Castro-Amarante
1, Cody Buchmann
1, Yoshimi Enoso-Akahata
5, Claudio Fenezia
1, Dustin Edwards
1, Luiz Carlos Junior Alcantara
1,2,3, Izabela Bialuk
1,4, Steven Jacobson
5, Bernardo Galvao-Castro
2,3, Antoine Gessain
6, Genoveffa Franchini
1
Cynthia Pise-Masison
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Cynthia Pise-Masison
Maria Fernanda de Castro-Amarante
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Maria Fernanda de Castro-Amarante
Cody Buchmann
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Cody Buchmann
Yoshimi Enoso-Akahata
5Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Find articles by Yoshimi Enoso-Akahata
Claudio Fenezia
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Claudio Fenezia
Dustin Edwards
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Dustin Edwards
Luiz Carlos Junior Alcantara
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
2Oswaldo Cruz Foundation Salvador, Bahia, Brazil
3HTLV Center/ Bahia School of Medicine and Public Health, Salvador, Bahia, Brazil
Find articles by Luiz Carlos Junior Alcantara
Izabela Bialuk
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
4Department of General and Experimental Pathology, Medical University of Bialystok, Bialystok, Poland
Find articles by Izabela Bialuk
Steven Jacobson
5Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
Find articles by Steven Jacobson
Bernardo Galvao-Castro
2Oswaldo Cruz Foundation Salvador, Bahia, Brazil
3HTLV Center/ Bahia School of Medicine and Public Health, Salvador, Bahia, Brazil
Find articles by Bernardo Galvao-Castro
Antoine Gessain
6Epidémiologie et Physiopathologie des Virus Oncogènes, CNRS URA3015, Pasteur Institute, Paris, Cedex 15, France
Find articles by Antoine Gessain
Genoveffa Franchini
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
Find articles by Genoveffa Franchini
1Animal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, MD, USA
2Oswaldo Cruz Foundation Salvador, Bahia, Brazil
3HTLV Center/ Bahia School of Medicine and Public Health, Salvador, Bahia, Brazil
4Department of General and Experimental Pathology, Medical University of Bialystok, Bialystok, Poland
5Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
6Epidémiologie et Physiopathologie des Virus Oncogènes, CNRS URA3015, Pasteur Institute, Paris, Cedex 15, France
✉
Corresponding author.
Supplement
16th Interntional Conference on Human Retroviruses: HTLV and Related Viruses
Benoit Barbeau
Conference
26-30 June 2013
16th International Conference on Human Retroviruses: HTLV and Related Viruses
Montreal, Canada
Collection date 2014.
Copyright © 2014 Pise-Masison et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
PMCID: PMC4044360
